TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05690555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Physical Therapy (PFPT)
Description: Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Pelvic Floor Physical Therapy (PFPT)
Description: Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative PFPT and Postoperative PFPT
Description: Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-over Treatment
Description: Any patients in the No PFPT arm who are determined to have pelvic floor dysfunction or symptoms that may benefit from PFPT referral, will be referred after the 12-week mark. Any patient in one of the PFPT arms who is determined to still need PFPT for persistent pelvic floor dysfunction or symptoms will be referred for continued care.
Study: NCT03395912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention
Description: After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
Study: NCT04469114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
Study: NCT03120546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rigid video stylet intubation
Description: intubation using rigid video stylet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rigid video stylet intubation
Description: intubation using rigid video stylet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope intubation
Description: intubation using video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope intubation
Description: intubation using video laryngoscope
Study: NCT02809690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAT
Description: Undergo 18F-FMAU PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMAU
Description: Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FMAU PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo TRUS-guided biopsy
Study: NCT01199289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection.
Study: NCT04355325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified monolithic zirconia crowns
Description: outcomes and complications of implant restoration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: modified monolithic zirconia crowns
Description: outcomes and complications of implant restoration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Ceramic crowns
Description: outcomes and complications of implant restoration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Metal Ceramic crowns
Description: outcomes and complications of implant restoration
Study: NCT01852942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet by mouth daily
Study: NCT01154218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC
Study: NCT00874354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracoronary Transplantation of Bone Marrow Stem Cells
Description: Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
Study: NCT03631901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral melatonin
Description: Both melatonin and diazepam were given only during the febrile illness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral diazepam
Description: Both melatonin and diazepam were given only during the febrile illness.
Study: NCT03613935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 1
Description: Comparison with products 2, 3, and 4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 1
Description: Comparison with products 2, 3, and 4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 1
Description: Comparison with products 2, 3, and 4
Study: NCT00880958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of various probiotics and fermentation products

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00787176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate
Description: The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
Study: NCT04094584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol (Extended Release Naltrexone)
Description: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
Study: NCT01189305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy
Description: Behavioral Couples Therapy
Study: NCT01625988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Study: NCT01189305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling
Description: Individual Drug Counseling
Study: NCT02717130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT04777266

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy and treatment as usual
Description: The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
Study: NCT02264847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotrophin
Description: Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate alone
Description: clomiphene citrate alone without hCG trigger
Study: NCT04777266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy and treatment as usual
Description: The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
Study: NCT02686476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
Study: NCT01030874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition/Salt intake
Description: Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Recommendations
Description: The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
Study: NCT01767272

Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: fexofenadine brand name

Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: fexofenadine brand name

Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: fexofenadine brand name
Study: NCT01775657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thopaz (Digital drainage)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thopaz (Digital drainage)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleur Evac (Analogue drainage)
Study: NCT01625988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02784561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)
Description: busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine(Actavis Italy S.p.A)
Description: cytarabine (1.6 g/m2/day, days -7 to -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Bayer)
Description: fludarabine (30 mg/m2, day -7 to -3),
Study: NCT01767272

Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: fexofenadine brand name

Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: fexofenadine brand name
Study: NCT00549770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study: NCT02784561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (KirinKunpeng)
Description: granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit ATG（Sanofi/Genzyme）
Description: ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
Study: NCT00549770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03624452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rIPC + Exercise
Description: The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rIPC only
Description: Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
Study: NCT04330781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral stent
Description: Radiotherapy with intraoral stent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intraoral stent
Description: Radiotherapy without intraoral stent
Study: NCT03394157

Intervention type: OTHER
Group type: OTHER
Intervention: metabolic surgery
Description: operation to cure type2 diabetes
Study: NCT02521272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow.
Description: Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air pocket
Description: Zero air pocket or one-liter air pocket in the snow.
Study: NCT01682811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan injection
Description: Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan surface application
Description: Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan surface application twice
Description: Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
Study: NCT02283307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced contrast DECT scan
Description: Subjects will undergo a dual energy CT scan with reduced contrast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard contrast SECT scan
Description: Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
Study: NCT00547040

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01259453

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination to prevent hepatitis B virus infection
Description: Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination to prevent hepatitis B virus infection
Description: Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
Study: NCT04293302

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01775657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleur Evac (Analogue drainage)
Study: NCT03507049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iFuse
Description: ifuse will be implanted as described in section on the active comparator arm of the study.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: sham surgery will be performed as desrcribed in section on sham comparator.

Intervention type: RADIATION
Group type: OTHER
Intervention: fMRI study
Description: Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.